iTeos Therapeutics Soars 27.55% on GlaxoSmithKline Partnership

On May 28, 2025, iTeos Therapeutics surged by 27.55% in pre-market trading, marking a significant rise in its stock value.

iTeos Therapeutics has recently been in the spotlight due to its strategic partnership with GlaxoSmithKline. The two companies announced an agreement to co-develop a new therapeutic, with both parties sharing responsibility and costs for the global development and commercialization of the drug. This collaboration is expected to accelerate the development process and bring innovative treatments to patients more quickly.

This partnership is a testament to iTeos Therapeutics' growing reputation in the biotech industry. The company's focus on immuno-oncology and its innovative approach to drug development have attracted the attention of major pharmaceutical companies. The collaboration with GlaxoSmithKline is likely to enhance iTeos Therapeutics' market position and drive future growth.